|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2001-3-22
|
|
pubmed:abstractText |
In inflamed skin, keratinocytes and inflammatory cells both produce large amounts of tumour necrosis factor (TNF) -alpha, a cytokine with broad effects that are relevant to inflammation. Blockade of this proinflammatory cytokine by a monoclonal anti-TNF-alpha antibody might be effectively used in the treatment of inflammatory skin diseases.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0007-0963
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
144
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
587-9
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11260020-Antibodies, Monoclonal,
pubmed-meshheading:11260020-Antirheumatic Agents,
pubmed-meshheading:11260020-Arthritis, Psoriatic,
pubmed-meshheading:11260020-Dermatologic Agents,
pubmed-meshheading:11260020-Disease Progression,
pubmed-meshheading:11260020-Drug Resistance,
pubmed-meshheading:11260020-Humans,
pubmed-meshheading:11260020-Methotrexate,
pubmed-meshheading:11260020-Psoriasis,
pubmed-meshheading:11260020-Severity of Illness Index,
pubmed-meshheading:11260020-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate.
|
|
pubmed:affiliation |
Departments of Dermatology and Medicine III, University of Erlangen, Hartmannstr. 14, D-91052 Erlangen, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
